Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group.

ABSTRACT:

Background

Treatment for pediatric psoriasis is challenging because of the lack of real-world evidence, especially for biological therapies.

Objectives

This study evaluated the efficacy and safety of biologics in children with psoriasis based on real-world evidence.

Methods

Pediatric psoriasis patients aged <18 years who were treated with biologics in our hospital (2020-2022) were prospectively analyzed. Patients treated with adalimumab, secukinumab, or ixekizumab were followed up for at least 16 weeks, and 22 of 38 patients completed the 52-week observation period. Dermatologist raters were blinded to ensure the reliability of the PASI, BSA, and PGA score assessments. PASI 75 or PGA 0/1 at week 12 represented an efficient indicator.

Results

Thirty-eight patien

SUBMITTER: Zheng YX 

PROVIDER: S-EPMC9490006 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature